The administration of chelation therapy to treat significant intakes of actinides, such as plutonium, affects the actinide's normal biokinetics. In particular, it enhances the actinide's rate of excretion, such that the standard biokinetic models cannot be applied directly to the chelation-affected bioassay data in order to estimate the intake and assess the radiation dose. The present study proposes a new chelation model that can be applied to the chelation-affected bioassay data after plutonium intake via wound and treatment with DTPA. In the proposed model, chelation is assumed to occur in the blood, liver, and parts of the skeleton. Ten datasets, consisting of measurements of C-DTPA, Pu, and Pu involving humans given radiolabeled DTPA and humans occupationally exposed to plutonium via wound and treated with chelation therapy, were used for model development. The combined dataset consisted of daily and cumulative excretion (urine and feces), wound counts, measurements of excised tissue, blood, and post-mortem tissue analyses of liver and skeleton. The combined data were simultaneously fit using the chelation model linked with a plutonium systemic model, which was linked to an ad hoc wound model. The proposed chelation model was used for dose assessment of the wound cases used in this study.

中文翻译：

---

新螯合模型的开发：通过伤口摄入钚和用 DTPA 治疗后的生物测定数据解释和剂量评估。

使用螯合疗法治疗大量摄入锕系元素，如钚，会影响锕系元素的正常生物动力学。特别是，它提高了锕系元素的排泄率，因此标准生物动力学模型不能直接应用于受螯合影响的生物测定数据，以估计摄入量和评估辐射剂量。本研究提出了一种新的螯合模型，该模型可应用于经伤口摄入钚和 DTPA 治疗后受螯合影响的生物测定数据。在所提出的模型中，假设螯合发生在血液、肝脏和骨骼的一部分中。十个数据集，包括 C-DTPA、Pu 和 Pu 的测量值，涉及给予放射性标记 DTPA 的人类和通过伤口职业性暴露于钚并接受螯合疗法治疗的人类，用于模型开发。组合数据集包括每日和累积排泄量（尿液和粪便）、伤口计数、切除组织、血液的测量值以及肝脏和骨骼的死后组织分析。使用与钚系统模型相关联的螯合模型同时拟合组合数据，该模型与特设伤口模型相关联。所提出的螯合模型用于本研究中使用的伤口病例的剂量评估。